Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Dr. Shirly Grynberg

  • Ella Lemelbaum Institute for Immuno-Oncology
  • Clinical Oncology
  • Melanoma
  • Skin Tumors
  • Immunotherapy
  • Personalized Medicine
  • English
  • Hebrew


Dr. Shirly Grynberg is a senior oncologist at the Ella Lemelbaum Institute for Immuno-Oncology. Since 2015, she has been an integral part of Sheba Medical Center, focusing on clinical oncology with a special emphasis on melanoma and skin tumors. Dr. Grynberg is renowned for her expertise in immunotherapy and personalized medicine, contributing significantly to advancing these fields through both her clinical practice and research initiatives. Her role includes educating future medical professionals and leading clinical studies, underlining her commitment to both patient care and academic excellence.

Conditions and treatment

  • Clinical Oncology
  • Melanoma
  • Skin Tumors
  • Immunotherapy
  • Personalized Medicine


  • 2023 - Present: Head of Integrated Practice Unit (IPU) for Melanoma and Skin Cancer, Sheba Medical Center
  • 2022 - Present: Head of the Oncology Residency Program, Sheba Medical Center
  • 2021 - Present: Senior Oncologist, Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Oncology Department, Sheba Medical Center

Education and Training

  • B.Sc. (Honors), The George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel (2010)
  • M.D., The Sackler School of Medicine, Tel Aviv University, Israel (2015)
  • Advanced Cardiovascular Life Support (ACLS): 2015, 2017, 2019, 2021
  • Good Clinical Practice (GCP): 2017, 2023
  • School of Continuing Medical Education, Tel Aviv University, Medical Oncology: 2018-2019

Board Certifications

  • 2015: The Dean's Award for Excellence in Clinical Years, The Sackler School of Medicine, Tel Aviv University
  • 2015: Excellence Grade for M.D. Thesis, The Sackler School of Medicine, Tel Aviv University
  • 2010: B.Sc. with Honors, The George S. Wise Faculty of Life Sciences, Tel Aviv University


Rozendorn N, Shutan I, Feinmesser G, Grynberg S, et al. "Real World Outcomes of Inoperable and Metastatic Cutaneous Head and Neck Melanoma Patients." Laryngoscope. January 17, 2024.

Grynberg S, Vered M, Shapira Frommer R, et al. "Neoadjuvant BRAF Targeted Therapy for Ameloblastoma of the Mandible: an Organ Preservation Approach." J Natl Cancer Inst. Published online November 15, 2023.

Stoff R., Grynberg, S., Asher, N., Laks, S., Steinberg, Y., Schachter, J., ... & Ben Betzalel, G.* "Efficacy and toxicity of Ipilimumab Nivolumab combination therapy in elderly metastatic melanoma patients." Frontiers in Oncology, 6158.

Stoff R, Ben Betzalel G, Grynberg S. "Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma." Frontiers in Oncology. 2023;13:1180988.

Pepys J, Grynberg S, Frommer RS, Schachter J, Asher N, Taliansky A, Nikitin V, Dori A. "Incidence and Outcome of Neurologic Immune Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma." Neurology. 2023.

Nethanel A, Grynberg S, Haik J, Debby A. "The Implications of a Dermatopathologist’s Report on Melanoma Diagnosis and Treatment." Life. 2023;24(9):1803.

Bar-Hai N, Ben Betzalel G, Stoff R, Grynberg S, Asher. "Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy." Cancers. 15(11), 3041.

Mor E, Grynberg S, Laks. "PET CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy." Surgical Oncology European Journal of Surgical Oncology. 2023.

Grynberg S, Stoff R, Asher N, et al. "Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients." Therapeutic Advances in Medical Oncology. 2022;14.

Mor E, Grynberg S, Stoff R, Adileh M, Steinberg Silman Y, Shapira Frommer R, Schachter J. "The increasing role of abdominal metastasectomy for malignant melanoma in the era of modern therapeutics." Surgical Oncology. 2022 Jul 9:101808.

Raphael A, Grynberg S, Dudnik E. "The Impact of Comprehensive Genomic Profiling (CGP) on the Decision Making Process in the Treatment of ALK Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd Generation ALK Tyrosine Kinase Inhibitors (TKIs)." Frontiers in Oncology. 2022;12:526.

Tamir A, Harati H, Asher N, Stoff R, Grynberg S, Markel G. "Removal of soluble tumor necrosis factors receptors 1/2 in patients with metastatic solid tumors using immune apheresis." Journal for ImmunoTherapy of Cancer. 2021 Nov 1;Suppl 2:A556.

Grynberg S, Lachish T, Kopel E, Meltzer E, Schwartz E. "Artemether lumefantrine compared to atovaquone proguanil as a treatment for uncomplicated Plasmodium falciparum malaria in travelers." Am J Trop Med Hyg. 2015 Jan;92(1):13-7. doi: 10.4269/ajtmh.14-0249. Epub 2014 Nov 4. PMID: 25371188; PMCID: PMC4347368.

Request a consultation

Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.

We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.

Request a consultation and a Sheba Case Manager will contact you shortly: